Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
immunotherapy
non-small cell lung cancer
pembrolizumab
smoking
tobacco
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
11
12
2020
revised:
05
01
2021
accepted:
06
01
2021
pubmed:
3
2
2021
medline:
20
11
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Improved outcome in tobacco smoking patients with non-small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first-line immunotherapy in patients with high PD-L1 expression. In this study we compared clinical outcomes according to the smoking status of two large multicenter cohorts. We compared clinical outcomes according to the smoking status (never smokers vs. current/former smokers) of two retrospective multicenter cohorts of metastatic NSCLC patients, treated with first-line pembrolizumab and platinum-based chemotherapy. A total of 962 NSCLC patients with PD-L1 expression ≥50% who received first-line pembrolizumab and 462 NSCLC patients who received first-line platinum-based chemotherapy were included in the study. Never smokers were confirmed to have a significantly higher risk of disease progression (hazard ratio [HR] = 1.49 [95% CI: 1.15-1.92], p = 0.0022) and death (HR = 1.38 [95% CI: 1.02-1.87], p = 0.0348) within the pembrolizumab cohort. On the contrary, a nonsignificant trend towards a reduced risk of disease progression (HR = 0.74 [95% CI: 0.52-1.05], p = 0.1003) and death (HR = 0.67 [95% CI: 0.45-1.01], p = 0.0593) were reported for never smokers within the chemotherapy cohort. After a random case-control matching, 424 patients from both cohorts were paired. Within the matched pembrolizumab cohort, never smokers had a significantly shorter progression-free survival (PFS) (HR = 1.68 [95% CI: 1.17-2.40], p = 0.0045) and a nonsignificant trend towards a shortened overall survival (OS) (HR = 1.32 [95% CI: 0.84-2.07], p = 0.2205). On the contrary, never smokers had a significantly longer PFS (HR = 0.68 [95% CI: 0.49-0.95], p = 0.0255) and OS (HR = 0.66 [95% CI: 0.45-0.97], p = 0,0356) compared to current/former smoker patients within the matched chemotherapy cohort. On pooled multivariable analysis, the interaction term between smoking status and treatment modality was concordantly statistically significant with respect to ORR (p = 0.0074), PFS (p = 0.0001) and OS (p = 0.0020), confirming the significantly different impact of smoking status across the two cohorts. Among metastatic NSCLC patients with PD-L1 expression ≥50% receiving first-line pembrolizumab, current/former smokers experienced improved PFS and OS. On the contrary, worse outcomes were reported among current/former smokers receiving first-line chemotherapy.
Sections du résumé
BACKGROUND
Improved outcome in tobacco smoking patients with non-small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first-line immunotherapy in patients with high PD-L1 expression. In this study we compared clinical outcomes according to the smoking status of two large multicenter cohorts.
METHODS
We compared clinical outcomes according to the smoking status (never smokers vs. current/former smokers) of two retrospective multicenter cohorts of metastatic NSCLC patients, treated with first-line pembrolizumab and platinum-based chemotherapy.
RESULTS
A total of 962 NSCLC patients with PD-L1 expression ≥50% who received first-line pembrolizumab and 462 NSCLC patients who received first-line platinum-based chemotherapy were included in the study. Never smokers were confirmed to have a significantly higher risk of disease progression (hazard ratio [HR] = 1.49 [95% CI: 1.15-1.92], p = 0.0022) and death (HR = 1.38 [95% CI: 1.02-1.87], p = 0.0348) within the pembrolizumab cohort. On the contrary, a nonsignificant trend towards a reduced risk of disease progression (HR = 0.74 [95% CI: 0.52-1.05], p = 0.1003) and death (HR = 0.67 [95% CI: 0.45-1.01], p = 0.0593) were reported for never smokers within the chemotherapy cohort. After a random case-control matching, 424 patients from both cohorts were paired. Within the matched pembrolizumab cohort, never smokers had a significantly shorter progression-free survival (PFS) (HR = 1.68 [95% CI: 1.17-2.40], p = 0.0045) and a nonsignificant trend towards a shortened overall survival (OS) (HR = 1.32 [95% CI: 0.84-2.07], p = 0.2205). On the contrary, never smokers had a significantly longer PFS (HR = 0.68 [95% CI: 0.49-0.95], p = 0.0255) and OS (HR = 0.66 [95% CI: 0.45-0.97], p = 0,0356) compared to current/former smoker patients within the matched chemotherapy cohort. On pooled multivariable analysis, the interaction term between smoking status and treatment modality was concordantly statistically significant with respect to ORR (p = 0.0074), PFS (p = 0.0001) and OS (p = 0.0020), confirming the significantly different impact of smoking status across the two cohorts.
CONCLUSIONS
Among metastatic NSCLC patients with PD-L1 expression ≥50% receiving first-line pembrolizumab, current/former smokers experienced improved PFS and OS. On the contrary, worse outcomes were reported among current/former smokers receiving first-line chemotherapy.
Identifiants
pubmed: 33527756
doi: 10.1111/1759-7714.13852
pmc: PMC7952794
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-889Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Cancers (Basel). 2020 May 17;12(5):
pubmed: 32429547
Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221
pubmed: 32474768
Clin Lung Cancer. 2015 Sep;16(5):325-33
pubmed: 25862554
Immunotherapy. 2019 Feb;11(3):189-199
pubmed: 30730276
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33077515
Lancet Respir Med. 2019 Apr;7(4):347-357
pubmed: 30876831
Clin Lung Cancer. 2020 Nov;21(6):498-508.e2
pubmed: 32680806
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Oncotarget. 2019 Nov 12;10(61):6604-6622
pubmed: 31762941
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Thorac Cancer. 2021 Mar;12(6):880-889
pubmed: 33527756
Ann Oncol. 2020 Sep;31(9):1112-1114
pubmed: 32771305
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Thorac Cancer. 2020 Feb;11(2):205-215
pubmed: 31799812
J Thorac Oncol. 2020 Jun;15(6):914-947
pubmed: 32179179
Oncotarget. 2017 Jun 28;8(54):93149-93155
pubmed: 29190984
Ann Oncol. 2020 Sep;31(9):1115-1118
pubmed: 32771306
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Ann Oncol. 2020 Mar;31(3):404-411
pubmed: 32067682
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Lung Cancer. 2019 Aug;134:174-179
pubmed: 31319978
Nat Commun. 2019 Mar 8;10(1):1125
pubmed: 30850589
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128